Tillkännagivande • Mar 25
Making Science Group, S.A. announces Annual dividend, payable on April 30, 2026 Making Science Group, S.A. announced Annual dividend of EUR 0.1799 per share payable on April 30, 2026, ex-date on April 28, 2026 and record date on April 29, 2026. Tillkännagivande • Feb 17
Making Science Group, S.A., Annual General Meeting, Mar 18, 2026 Making Science Group, S.A., Annual General Meeting, Mar 18, 2026. Location: calle lopez de hoyos 135, 3., madrid Spain New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.3% average weekly change). Market cap is less than US$100m (€67.0m market cap, or US$78.0m). New Risk • Oct 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Market cap is less than US$100m (€78.0m market cap, or US$91.3m). Reported Earnings • May 23
Full year 2024 earnings released: €0.20 loss per share (vs €0.46 loss in FY 2023) Full year 2024 results: €0.20 loss per share (improved from €0.46 loss in FY 2023). Revenue: €273.5m (up 16% from FY 2023). Net loss: €1.72m (loss narrowed 55% from FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Tillkännagivande • May 12
Making Science Group, S.A., Annual General Meeting, Jun 12, 2025 Making Science Group, S.A., Annual General Meeting, Jun 12, 2025. Location: calle lopez de hoyos 135, 3., madrid Spain New Risk • May 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€77.0m market cap, or US$86.6m). New Risk • Feb 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Market cap is less than US$100m (€81.4m market cap, or US$84.7m). Tillkännagivande • Jan 09
Making Science Launches RAISING, Its New AI Technology Division to Power Marketing Strategies Making Science has announced the launch of RAISING, its new technology division that combines the company's business expertise with data science to develop advanced solutions based on Artificial Intelligence. This new venture aims to transform brands' marketing strategies through predictive, generative, and automated AI technologies, optimizing results throughout the entire funnel. RAISING integrates cutting-edge tools that reinforce its technology proposition. These include ad-machina, Making Science's technology that uses generative AI to automate the creation and multi-platform activation of personalized ads in real-time. The tool has proven its effectiveness on platforms such as Performance Max and Meta, achieving up to 30% more conversions compared to traditional methods. Its advanced functionalalities allow the dynamic adaptation of text, image, or video ads to market and user needs, incorporating detailed data analysis, automatic translation, and large-scale optimization, ensuring more effective and profitable campaigns, which relevant companies such as Banco Santander or MediaMarkt have already integrated into their business plans. Another key product of this new division is Gauss AI, which is designed to predict user behavior and optimize distribution, measurement, and media planning strategies. This system helps companies to identify the most relevant and profitable interactions, increasing the effectiveness of their campaigns. Trust Generative AI is positioned as a versatile and secure tool for content generation at scale, automating internal and external processes in areas such as marketing, SEO, and human resources while ensuring regulatory compliance and ultimate human control. The launch of RAISING reinforces Making Science's position as a benchmark in technological innovation applied to marketing. New Risk • Dec 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (€68.6m market cap, or US$71.5m). New Risk • Nov 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (€73.9m market cap, or US$78.1m). Tillkännagivande • Nov 19
Making Science Announces Management Changes Making Science has announced the appointment of Nick Waters as CEO for the UK, Northern and Central Europe. Based in London, with extensive experience in business leadership and the technology market, Waters will be responsible for driving the company’s growth and expansion across Europe. Due to take up the role in February 2025, Waters brings over 20 years of experience in international media, digital, and advertising. He joins Making Science from Ebiquity Plc, where he was Group Chief Executive Officer. Before that, he spent 10 years at Dentsu Aegis Network – latterly as Executive Chairman UK & Ireland, and 12 years at Mindshare, rising to regional CEO of Europe, Middle East, and Africa. Waters’ appointment follows the announcement of Marcus Cooper as Business Director, UK, Brad Beiter as SVP of Customer Management, and José Luis Pulpón, (ex Google) as Managing Director for Making Science, Spain. These strategic hires play a vital role in Making Science’s global expansion to ensure the delivery of cutting-edge digital transformation solutions for its clients across industries. Reported Earnings • Oct 24
Second quarter 2023 earnings released Second quarter 2023 results: €0.12 loss per share. Revenue: €57.0m (up 15% from 2Q 2022). Net loss: €1.03m (loss widened 35% from 2Q 2022). New Risk • Aug 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (4.1% average weekly change). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€71.4m market cap, or US$78.7m). New Risk • Jul 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€69.6m market cap, or US$75.4m). Tillkännagivande • May 21
Making Science Group, S.A., Annual General Meeting, Jun 17, 2024 Making Science Group, S.A., Annual General Meeting, Jun 17, 2024. Location: calle lopez de hoyos 135, 3., madrid Spain New Risk • May 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€74.2m market cap, or US$80.6m). New Risk • May 16
New major risk - Revenue and earnings growth Earnings have declined by 65% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€74.4m market cap, or US$80.9m). New Risk • Apr 18
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Market cap is less than US$100m (€72.8m market cap, or US$77.7m). New Risk • Nov 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (5.3% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€79.0m market cap, or US$84.7m). New Risk • Oct 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€69.0m market cap, or US$73.0m). New Risk • Oct 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 3.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (3.8% average weekly change). Market cap is less than US$100m (€69.6m market cap, or US$73.0m). Reported Earnings • Apr 20
Full year 2022 earnings released Full year 2022 results: Revenue: €213.4m (up 89% from FY 2021). Net loss: €4.99m (loss widened 43% from FY 2021). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorated over the past week After last week's 19% share price decline to €13.80, the stock trades at a trailing P/E ratio of 67x. Average trailing P/E is 7x in the Media industry in Spain. Total loss to shareholders of 45% over the past year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Apr 17
Full year 2020 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.9m (up 130% from FY 2019). Net income: €1.54m (up 302% from FY 2019). Profit margin: 2.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 28
New 90-day high: €28.00 The company is up 103% from its price of €13.80 on 30 November 2020. The Spanish market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 10.0% over the same period. Is New 90 Day High Low • Feb 06
New 90-day high: €15.50 The company is up 20% from its price of €12.90 on 06 November 2020. The Spanish market is up 16% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Media industry, which is also up 20% over the same period. Is New 90 Day High Low • Nov 04
New 90-day high: €12.30 The company is up 108% from its price of €5.90 on 05 August 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 5.0% over the same period. Is New 90 Day High Low • Oct 09
New 90-day high: €7.05 The company is up 19% from its price of €5.90 on 10 July 2020. The Spanish market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 13% over the same period. Tillkännagivande • Jul 17
Making Science Group, S.A. (BME:MAKS) signed a deal to acquire Salesforce associated assets of Cloudforms SL. Making Science Group, S.A. (BME:MAKS) signed a deal to acquire Salesforce associated assets of Cloudforms SL on July 14, 2020. After acquisition, Making Science expects a gross margin growth of €0.5 million and EBITDA growth of €0.1 million over the next 12 months.